



(51) International Patent Classification:

C07D 213/84 (2006.01) **A61K 31/44** (2006.01)
A61K 31/416 (2006.01) **A61K 31/47** (2006.01)
A61K 31/4164 (2006.01) **A61K 31/506** (2006.01)
A61K 31/42 (2006.01) **C07D 215/22** (2006.01)
A61K 31/423 (2006.01) **C07D 231/56** (2006.01)
A61K 31/4245 (2006.01) **C07D 233/70** (2006.01)
A61K 31/4355 (2006.01) **C07D 239/34** (2006.01)
A61K 31/4365 (2006.01)

(21) International Application Number:

PCT/EP2013/062995

(22) International Filing Date:

21 June 2013 (21.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/664,398 26 June 2012 (26.06.2012) US
 61/763,206 11 February 2013 (11.02.2013) US

(71) **Applicant:** LEO LABORATORIES LIMITED [IE/IE];
285 Cashel Road, Crumlin, Dublin 12 (IE).

(72) **Inventors:** LIANG, Xifu; LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). HÖGBERG, Thomas; LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). NØRREMARK, Bjarne; LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). MÅNS-SON, Kristoffer; LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). RYTTERSGAARD, Carsten; LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). GRUE-SØRENSEN, Gunnar; Thyrasvej 3, DK-4000 Roskilde (DK).

(74) **Agent:** LEO PHARMA A/S; Attn. Patents, Industriparken 55, DK-2750 Ballerup (DK).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) **Date of publication of the international search report:**

27 February 2014

(54) **Title:** 3-O-HETEROARYL-INGENOL



(57) **Abstract:** The present invention relates to a compound according to formula (I) wherein R₁ represents optionally substituted heteroaryl, and pharmaceutically acceptable salts, hydrates, solvates or pharmaceutically acceptable and physiologically cleavable esters thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. diseases associated with hyperplasia, neoplasia or dysplasia, with said compounds, to methods of treatment of cosmetic indications with said compounds, and to the use of said compounds in the manufacture of medicaments.